Is ACT a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Enact Holdings (ACT) rests on Insurance in force compounding on high persistency: Earned premium is a function of how much insurance stays on the books, not how much is written in any single quarter. The bear case rests on enact is a concentrated bet on US mortgage credit, with essentially one product, one country and one collateral type. Analysts covering it publish targets from $40.00 to $51.00 against a $45.75 share price on November 16, 2026, so even the professionals disagree by 23% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
ACT key stats
At $45.75 on November 16, 2026, Enact Holdings (ACT) has a market cap of $6.1B, a P/E of 9.6 on trailing earnings (9.1 on forward earnings) and a dividend yield of 2.10%.
- Market cap
- $6.1B
- P/E (trailing)
- 9.6
- P/E (forward)
- 9.1
- EPS (trailing 12 months)
- $4.79
- Price to book
- 1.2
- Dividend yield
- 2.10%
- Beta
- 0.44
Market cap, P/E and yield are measured at the $45.75 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Enact Holdings (ACT)?
The last two weeks for Enact Holdings, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- ACT closed at $45.75 on November 16, 2026, down 2.1% over the past five trading days (from $46.71).
- On November 5, 2026, Enact Holdings filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 4, 2026, Enact Holdings filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 7, 2026, JP Morgan raised its target to $45.00 from $44.00 (Underweight).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Enact Holdings (Nasdaq: ACT) sells private mortgage insurance. When a borrower puts down less than 20% on a conventional loan sold to Fannie Mae or Freddie Mac, the GSEs require credit enhancement, and Enact is one of a handful of companies that provides it. The economics are simple to describe and slow to unwind: Enact writes a policy, collects a recurring premium for as long as the loan stays outstanding, and pays a claim only if the borrower defaults and the foreclosure proceeds fall short. That produces a large, slow-moving book. Primary insurance in force was about $274B as of the second quarter of 2026, up roughly 2% year over year, and new insurance written in the quarter was about $15.2B. Revenue is net premiums earned plus investment income on the reserve portfolio, and because the cost base is thin, the operating margin runs above 70%. The recent results reflect a benign credit environment more than a growth story. Second-quarter 2026 revenue was about $317M with net income near $175M, or about $1.25 per diluted share (adjusted EPS of ~$1.26 against a ~$1.19 consensus), and return on equity around 13%. Persistency has stayed high because borrowers holding low-rate mortgages have little reason to refinance, which keeps premium-paying policies on the books longer than the historical norm. Capital is abundant: PMIERs sufficiency was roughly 161%, about $1.9B above the required level, and management has pointed to $550M to $600M of total capital return for full-year 2026 through buybacks and the $0.24 quarterly dividend. Share count is down roughly 6% year over year. One structural feature dominates the shareholder register: Genworth Financial still owns about 81% of Enact, so the public float is small and Genworth's own capital needs influence how much cash Enact sends out. The stock closed at ~$46.21 on October 16, 2026, up ~17% year to date and ~32% over one year, for a market value of about $6.4 billion. It slipped after JPMorgan downgraded it to Underweight from Neutral on October 12, and mortgage insurers as a group traded down in early October. On October 1 Enact also added a forward quota share reinsurance transaction to its credit risk transfer program, and AM Best affirmed the ratings of Enact Re on October 2. Third-quarter results are due November 4, 2026, with the earnings call on November 5 and consensus near ~$1.20 EPS on ~$318 million of revenue.
The bull case: what would have to be true for $51.00
The most optimistic published target on ACT is $51.00, +11.5% from the $45.75 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Insurance in force compounding on high persistency
Earned premium is a function of how much insurance stays on the books, not how much is written in any single quarter. With a large share of outstanding mortgages carrying rates well below current market levels, refinancing is unattractive and policies persist, which lets in-force grow even when origination volumes are soft. That dynamic reverses if mortgage rates fall meaningfully, since a refinancing wave cancels existing policies and forces Enact to rewrite the book at prevailing prices.
2. Credit performance and reserve development
A meaningful slice of reported earnings in recent years has come from favorable reserve development, meaning delinquencies that Enact reserved against cured rather than went to claim. Home price appreciation is the mechanism: a borrower with equity sells rather than defaults. This is a real economic result but it is not the same as underwriting growth, and it is the line item most likely to swing if home prices flatten and unemployment rises.
3. Excess capital and the return program
PMIERs sufficiency around 161% and roughly $1.9B of capital above the compliance requirement give Enact room to fund buybacks and dividends without straining the regulatory position. Shares outstanding fell about 6% over the past year and the payout ratio sits near 18%, so the dividend is well covered. The pace of return is partly a Genworth decision given the 81% stake, which is a governance consideration as much as a capital one.
4. Reinsurance and risk transfer
Enact cedes a portion of its risk through quota-share treaties, excess-of-loss coverage and insurance-linked notes, and runs a Bermuda subsidiary, Enact Re, that assumes third-party mortgage credit risk. Ceding lowers required capital and smooths tail exposure at the cost of giving up premium. The availability and price of that reinsurance capacity is an external variable Enact does not control, and it tightens exactly when mortgage credit looks worst. Enact added to that program on October 1, 2026 with a forward quota share reinsurance transaction, and AM Best affirmed Enact Re's credit ratings the following day.
The bear case: what would have to be true for $40.00
The most pessimistic published target is $40.00, -12.6% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Enact Holdings is worth if the risks below bite instead of the drivers above.
Enact is a concentrated bet on US mortgage credit, with essentially one product, one country and one collateral type. A housing downturn combined with rising unemployment would raise delinquencies, turn favorable reserve development into reserve strengthening, and hit earnings faster than premiums could reprice. Policy risk is real and recurring: FHFA capital rules (PMIERs), GSE pricing through loan-level adjustments, and FHA premium changes can each shift the economics of private mortgage insurance without any change in Enact's own execution, since FHA is a direct substitute for the same borrower. Competition among the six private mortgage insurers runs through proprietary risk-based pricing engines that are not publicly disclosed, so price competition is difficult for outside investors to observe until it shows up in returns. Genworth's roughly 81% ownership means the public float is limited, minority holders have little influence, and Enact's capital return policy is shaped by a parent with its own funding needs including its CareScout long-term care initiatives. Analyst sentiment has cooled: JPMorgan moved the stock to Underweight in October 2026 and the five analysts tracked by Yahoo Finance had a hold consensus with a mean target of ~$49.40, while consensus EPS growth slows to ~3.7% in 2027. As of August 2026 no securities-fraud class action against Enact was identified in public filings or court dockets.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ACT already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on ACT
5 analysts cover ACT, with an average target of $47.00 (+2.7% against $45.75) and a split of 0 buy, 4 hold, 2 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ACT forecast and price target page.
How is ACT valued?
Market cap, P/E and dividend yield at today's price are in the ACT key stats above. The business figures below come from Enact Holdings's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$1.25B (Q2 2026 up ~4% yoy)
- Net income (TTM): ~$683M (~55% profit margin)
- Q2 2026 adj. EPS: ~$1.26 (vs ~$1.19 est.)
As of October 2026: At ~$46.21 on October 16, 2026, Enact trades near 9.8x trailing and ~9.2x forward earnings, slightly cheaper than in August after the JPMorgan downgrade, in line with how the market generally capitalizes mortgage insurers because reported profits include reserve releases that are not assumed to repeat through a credit cycle. Price to book near 1.2x with mid-teens ROE implies the market expects returns to normalize lower over time. Because roughly 81% of the shares sit with Genworth, the free float is thin, which affects liquidity and the practical relevance of index-driven flows.
How do you decide if ACT is a buy?
Whether ACT is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ACT indirectly through an index or sector ETF before adding more.
What would change your mind on ACT
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Insurance in force compounding on high persistency stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: enact is a concentrated bet on US mortgage credit, with essentially one product, one country and one collateral type fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the ACT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ACT against your real portfolio and see your actual exposure before deciding.
Your questions about Enact Holdings
Ask Walnut's AI anything about ACT and see how it fits what you own.
FAQ
Is ACT a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Insurance in force compounding on high persistency, with revenue (ttm) at ~$1.25B (Q2 2026 up ~4% yoy). The bear case rests on enact is a concentrated bet on US mortgage credit, with essentially one product, one country and one collateral type. Analysts covering it are spread from $40.00 to $51.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell ACT?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Enact is a concentrated bet on US mortgage credit, with essentially one product, one country and one collateral type. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $40.00, -12.6% from the $45.75 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for ACT?
+
Insurance in force compounding on high persistency. Earned premium is a function of how much insurance stays on the books, not how much is written in any single quarter. The most optimistic analyst target on ACT is $51.00, +11.5% from the $45.75 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for ACT?
+
Enact is a concentrated bet on US mortgage credit, with essentially one product, one country and one collateral type. A housing downturn combined with rising unemployment would raise delinquencies, turn favorable reserve development into reserve strengthening, and hit earnings faster than premiums could reprice. Policy risk is real and recurring: FHFA capital rules (PMIERs), GSE pricing through loan-level adjustments, and FHA premium changes can each shift the economics of private mortgage insurance without any change in Enact's own execution, since FHA is a direct substitute for the same borrower. Competition among the six private mortgage insurers runs through proprietary risk-based pricing engines that are not publicly disclosed, so price competition is difficult for outside investors to observe until it shows up in returns. Genworth's roughly 81% ownership means the public float is limited, minority holders have little influence, and Enact's capital return policy is shaped by a parent with its own funding needs including its CareScout long-term care initiatives. Analyst sentiment has cooled: JPMorgan moved the stock to Underweight in October 2026 and the five analysts tracked by Yahoo Finance had a hold consensus with a mean target of ~$49.40, while consensus EPS growth slows to ~3.7% in 2027. As of August 2026 no securities-fraud class action against Enact was identified in public filings or court dockets. The most pessimistic published target is $40.00, -12.6% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Enact Holdings do?
+
Enact Holdings is a US private mortgage insurer, majority owned by Genworth, that insures lenders against default on low-down-payment conventional GSE mortgages.
What would have to change for ACT to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Insurance in force compounding on high persistency) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (enact is a concentrated bet on US mortgage credit, with essentially one product, one country and one collateral type) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Enact Holdings do?
+
Enact writes private mortgage insurance in the United States. When a borrower makes a down payment below 20% on a conventional loan destined for Fannie Mae or Freddie Mac, the GSEs require credit enhancement, and Enact insures the lender against loss if that borrower defaults. It collects a recurring premium for the life of the policy and pays a claim only when a foreclosure produces a shortfall.
Is ACT the same company as Genworth Mortgage Insurance?
+
Yes, in origin. Enact was Genworth's US mortgage insurance business, rebranded and taken public through an IPO on Nasdaq in September 2021. Genworth Financial (GNW) retained a controlling stake and still owns roughly 81% of Enact as of the second quarter of 2026, so ACT trades with a limited public float and a controlled-company governance structure.
Does ACT stock pay a dividend?
+
Enact pays a quarterly cash dividend, most recently $0.24 per share, which annualizes to about $0.96 and works out to roughly a 2.1% yield at the October 16, 2026 share price of ~$46.21. The payout ratio is around 18% of earnings, and the company returns considerably more capital through buybacks than through the dividend, with shares outstanding down about 6% year over year.
Walnut is informational, not investment advice, and gives no verdict on ACT. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.